医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

S-Alpha Therapeutics, Inc., Digital Therapeutics Start-up Raises $8.7 Million in Series A Funding

2021年08月10日 AM01:45
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

On July 31st 2021, S-Alpha Therapeutics, Inc., (“S-Alpha” CEO: Seung-Eun Choi), a startup dedicated in R&D for digital therapeutics, announced the completion of its Series A financing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210809005608/en/

S-Alpha Therapeutics raised a total of $8.7M USD (10 Billion KRW) in Series A financing round with the participation by existing investors and new Venture Capitalist (VC) funding.

In 2020, S-Alpha Therapeutics raised $2.7M USD (3 Billion KRW) in seed round of funding from Hana Ventures, STIC Ventures, AJU IB Investment, SJ Investment Partners, and TONY Investment. In Series A funding, all existing investors participated in this investment, and Korea Investment Partners, Stonebridge Ventures, Devsisters Ventures/KDB Capital, and Timewise Investment participated as new investors.

“The convergence of information technology (IT) and biotechnology is an inevitable industry trend. The investment in this industry is the driving force for fast product development, verification of new concepts and enhances the development of disruptive technologies. It also provides resources and infrastructure for validating the safety as well as efficacy of the product” said STIC Ventures, which led this investment.

Dr. Yong-Sun Lee, Chief Strategy Officer from S-Alpha Therapeutics said “With this investment, we plan to develop and validate SAT-001, the leading product in pediatric myopia, through clinical trials in Korea and in US. S-Alpha Therapeutics will also use this fund to complete verification of SAT-008 and support R&D efforts to validate the concept in new disease areas of our pipeline.

About S-Alpha Therapeutics, Inc.

Founded in 2019, S-Alpha Therapeutics develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology. Company has developed several digital therapeutic products in its R&D pipeline.

Currently, company is conducting clinical trials to evaluate the efficacy, safety and feasibility of SAT-001 in several clinical sites in South Korea.

Among the company’s pipelines, SAT-008, developed for the purpose of inducing an individual’s immune-boosting effect, is in the process of establishing a business development model according to the evidence generated from clinical studies in South Korea. In addition, S-Alpha Therapeutics is in the process of developing other products in the pipeline.

www.salphadtx.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20210809005608/en/

CONTACT

For media contact: Sanghun Lee

email: sanghun@salphadtx.com

Phone : 82-2-3487-3923

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • CANbridge Pharmaceuticals to Participate in the Morgan Stanley Virtual China Summit 2022
  • エメンド・バイオセラピューティクスが次世代CRISPR遺伝子編集技術のアレル特異的手法によりELANE関連重症先天性好中球減少症の治療で達成した画期的成果をASGCT年次総会で発表
  • ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China
  • Taiwan Excellence’s “Smart Tech, Smart Clothing” Webinar Highlights Innovations from Taiwan for the Outdoor Industry
  • Exscientia将于2022年5月25日公布2022年第一季度业绩